IL-6 has also been implicated as a mediator of pulmonary fibrosis, regardless of ILD subtype18, with IL-6 blockade using tocilizumab reducing the rate of FVC decline in SSc-ILD19. The gene discussed is IL6; the disease is interstitial lung disease.